CATX SCHEDULE 13D/A: SEC filing
Lantheus Holdings and its subsidiaries
Filed with the SEC on · accession 0001193125-26-458595
CATX filed a SCHEDULE 13D/A (schedule 13d/a) with the SEC on Nov 12, 2026. A report the company filed with the SEC (the US market regulator).
Summary of the filing
Lantheus Holdings and its subsidiaries filed an amended Schedule 13D reporting beneficial ownership of 4,739,011 shares, or 3.9%, of Perspective Therapeutics common stock as of November 10, 2026.
Key details
✦ Ask GOAX AI about this filing — what it means for CATX, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for CATX?
Click hereFrequently asked questions
What did CATX file with the SEC on Nov 12, 2026?
CATX filed a SCHEDULE 13D/A (SEC filing). Lantheus Holdings and its subsidiaries filed an amended Schedule 13D reporting beneficial ownership of 4,739,011 shares, or 3.9%, of Perspective Therapeutics common stock as of November 10, 2026.
How do I read a SCHEDULE 13D/A?
A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13D/A (schedule 13d/a): A report the company filed with the SEC (the US market regulator).
Other CATX SEC filings
- SCHEDULE 13G · SEC filingNov 10, 2026
- 10-Q · SEC filingNov 9, 2026
- 8-K · SEC filingNov 9, 2026
- 8-K · SEC filingNov 6, 2026
- 8-K · SEC filingNov 6, 2026
- 8-K · SEC filingOct 23, 2026
- 8-K · Fda approvalOct 8, 2026
- 8-K · SEC filingOct 1, 2026
- SCHEDULE 13D/A · SEC filingSep 23, 2026
- 8-K · Material agreementSep 14, 2026
Get alerts when CATX files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days